STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-04-19
Here’s whether Gilead Sciences Inc (GILD) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 59 — healthy momentum range; strong 1-year return of +31.2%; 3-month momentum positive (+10.2%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 12.5% off its 52-week high. Score: +4/7.
GILD is holding above its long-term 200-day MA ($125.80) but has slipped below the 50-day MA ($144.49), pointing to short-term weakness in an otherwise intact trend. An RSI of 58.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +31.2% compares to +35.1% for SPY (trailed the market by 3.9%).
$10,000 invested 1 year ago→ $13,124 today
vs. S&P 500 (SPY) — same period trailed market by 3.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($125.80)
✗Above 50-day MA ($144.49)
✓RSI(14) neutral zone (30–70) — currently 58.9
✓Positive return (+31.2%)
!Within 10% of period high (−12.5%)
Period Range $137.64
$93.37$157.29
RSI (14) 58.9
0 · OversoldOverbought · 100
Key Metrics
Price$137.64
Period Return+31.2%
Period High$157.29
Period Low$93.37
Drawdown−12.5%
MA-50$144.49
MA-200$125.80
RSI (14)58.9
Avg Volume (30d)5.7M
vs. SPYtrailed by 3.9%
Return Rank#479 of 996
Trend Signals
Price is above the 200-day moving average ($125.80)
Price is below the 50-day moving average ($144.49)